{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'HR', 'Heart rate', 'HR-QoL', 'Health Related Quality of Life', 'HRT', 'Hormone replacement therapy', 'hsCRP', 'High sensitivity C-reactive protein', 'KDIGO', 'Kidney Disease Improving Global Outcomes', 'KDOQI', 'Kidney Disease Outcomes Quality Initiative', 'IB', \"Investigator's Brochure\", 'ICH', 'International Conference on Harmonization', 'IEC', 'Independent Ethics Committee', 'IRB', 'Institutional Review Board', 'IRT', 'Interactive Response Technology', 'ITT', 'Intent-to-treat', 'IV', 'Intravenous', 'LDH', 'Lactate dehydrogenase', 'LDL-C (direct)', 'Directly measured Low density lipoprotein-C', 'MACE', 'Major adverse cardiovascular event', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin concentration', 'MCV', 'Mean corpuscular volume', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MI', 'Myocardial infarction', 'MRI', 'Magnetic resonance imaging', 'MSDS', 'Material Safety Data Sheet', 'NYHA', 'New York Heart Association', 'PD', 'Peritoneal dialysis', 'PGI-C', 'Patient Global Impression of Change', 'PGI-S', 'Patient Global Impression of Severity', 'PHI', 'Prolyl hydroxylase inhibitor', 'PK', 'Pharmacokinetic', 'PSRAE', 'Possible Suicidality Related Adverse Events', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cell', 'RDW', 'Red blood cell distribution width', 'rhEPO', 'Recombinant human erythropoietin', 'SAE', 'Serious adverse event', 'SBP', 'Systolic blood pressure', 'SD', 'Standard deviation', 'SF-36', 'Short Form -36', 'sPAP', 'Systolic pulmonary artery pressure', 'SRM', 'Study Reference Manual', 'TIBC', 'Total iron binding capacity', 'TSAT', 'Transferrin saturation', 'UIBC', 'Unsaturated iron binding capacity', 'U', 'Units', 'ULN', 'Upper limit of normal', 'WBC', 'White blood cells', '75']['2016N298481_02', 'CONFIDENTIAL', '205270', 'WPAI-ANS-CPV', 'Work Productivity and Activity Impairment Questionnaire:', 'Anemic Symptoms Clinical Practice Version', 'Trademark Information', 'Trademarks of the GlaxoSmithKline', 'Trademarks not owned by the', 'group of companies', 'GlaxoSmithKline group of companies', 'NONE', 'ActiGraph GT9X Link', 'HemoCue', '76']['2016N298481_02', 'CONFIDENTIAL', '205270', '12.2.', 'Appendix 2: Study Governance Considerations', '12.2.1.', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with:', 'Consensus ethical principles derived from international guidelines', 'including the Declaration of Helsinki and Council for International', 'Organizations of Medical Sciences (CIOMS) International Ethical', 'Guidelines', 'Applicable International Conference on Harmonization (ICH) Good', 'Clinical Practice (GCP) Guidelines', 'Applicable laws and regulations', 'The protocol, protocol amendments, ICF, Investigator Brochure [IB', 'GlaxoSmithKline Document number RM2008/00267/07], and other relevant', 'documents (eg, advertisements) must be submitted to an IRB/IEC by the', 'investigator and reviewed and approved by the IRB/IEC before the study is', 'initiated.', 'The IEC/IRB, and where applicable the regulatory authority, approve the', 'clinical protocol and all optional assessments, including genetic research.', 'Optional assessments (including those in a separate protocol and/or under', 'separate informed consent) and the clinical protocol should be concurrently', 'submitted for approval unless regulation requires separate submission.', 'Approval of the optional assessments may occur after approval is granted for', 'the clinical protocol where required by regulatory authorities. In this', 'situation, written approval of the clinical protocol should state that approval', 'of optional assessments is being deferred and the study, with the exception of', 'the optional assessments, can be initiated', 'Any amendments to the protocol will require IEC/IRB approval before', 'implementation of changes made to the study design, except for changes', 'necessary to eliminate an immediate hazard to study participants.', 'The investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC', 'annually or more frequently in accordance with the requirements, policies,', 'and procedures established by the IRB/EC', 'Notifying the IRB/IEC of SAE or other significant safety findings as', 'required by IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European', 'regulation 536/2014 for clinical studies (if applicable), and all other', 'applicable local regulations', '77']\n\n###\n\n", "completion": "END"}